68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA)
(gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography
(PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying
prostate cancer that may have returned after a period of improvement (biochemical
recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer
receptor, which can then be imaged by the PET/CT or PET/MRI scanner.